Cassava Sciences amends bonus plan; ties CEO payout to FDA approval of simufilam

FILANA THERAPEUTICS, INC.

Amendments require Chairman/President/CEO bonus only if FDA approves simufilam, except in Merger Transaction.
Compensation Committee set all previously unallocated cash bonuses to zero and rescinded plan on Feb 13, 2025.
No cash bonuses have been paid to any participant under the CIB Plan through the filing date.
Changes result from shareholder derivative lawsuit settlement approved by Delaware Court of Chancery on Jan 24, 2025.
Market cap milestones up to $5B remain; bonuses deferred until Company has sufficient cash for 24 months.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.